IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk.
- Resource Type
- Editorial & Opinion
- Authors
- Kao KC; Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.; Jaccard A; Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.; Ho PC; Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
- Source
- Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
- Subject
- Language
- English
Summary: In this issue, Hu and colleagues unveil that IFNα administration combined with anti-PD-1 therapy can potentiate murine and human CD8+ T-cell antitumor response in hepatocellular carcinoma, highlighting a novel therapeutic strategy for hepatocellular carcinoma. See related article by Hu et al., p. 1718 (6) .
(©2022 American Association for Cancer Research.)